How decentralisation can fill the gaps in Alzheimer's research [Yahoo! Finance]
Lexeo Therapeutics, Inc. (NASDAQ: LXEO) had its price target raised by analysts at HC Wainwright from $21.00 to $23.00. They now have a "buy" rating on the stock.
Lexeo Therapeutics, Inc. (NASDAQ: LXEO) had its price target raised by analysts at Chardan Capital from $23.00 to $25.00. They now have a "buy" rating on the stock.
Lexeo Therapeutics, Inc. (NASDAQ: LXEO) had its price target lowered by analysts at Leerink Partners from $20.00 to $19.00. They now have an "outperform" rating on the stock.
Lexeo Therapeutics GAAP EPS of -$0.89 misses by $0.24 [Seeking Alpha]